Answers are grounded in this paper and cite their sources.
Objective: PD-L1 expression is a potential biomarker for predicting immunotherapy response, but its role in endometrial carcinoma (EC) is unclear. This study evaluated PD-L1 expression in tumor cells (TC), immune cells (IC), and by the combined positive score (CPS), and examined associations with mismatch repair (MMR) status, p53 immunophenotype, and clinicopathological features. Methods: A total of 299 EC cases were retrospectively analyzed. PD-L1 was assessed by immunohistochemistry using TC, IC, and CPS scoring. MMR proteins (MLH1, PMS2, MSH2, MSH6) and p53 expression were also evaluated, and correlations with histological subtype, grade, and clinical parameters were examined. Results: PD-L1 positivity was observed in 33.9% of IC, 16.2% of TC, and 35.7% of CPS cases. IC and CPS expression were significantly associated with low-grade tumors (p < 0.001). MMR-deficient tumors demonstrated higher PD-L1 expression across all scoring methods (p < 0.001 for IC/CPS; p = 0.020 for TC). In addition, p53 mutation correlated with MMR stability (p = 0.014) and with PD-L1 TC positivity (p = 0.044). Conclusion: PD-L1 expression in TC correlated with p53 status and was linked to MMR deficiency. Combined evaluation of PD-L1, MMR, and p53 may aid stratification and guide immunotherapy in EC.
No takes yet. Share an insight, caveat, or question.
Karakaya et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: